These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25839898)

  • 41. Antidepressant-like properties of sarizotan in experimental Parkinsonism.
    Zhang X; Egeland M; Svenningsson P
    Psychopharmacology (Berl); 2011 Dec; 218(4):621-34. PubMed ID: 21647579
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
    Fiorentini C; Savoia P; Savoldi D; Barbon A; Missale C
    Neurobiol Dis; 2013 Jun; 54():339-48. PubMed ID: 23328768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baicalin Modulates APPL2/Glucocorticoid Receptor Signaling Cascade, Promotes Neurogenesis, and Attenuates Emotional and Olfactory Dysfunctions in Chronic Corticosterone-Induced Depression.
    Gao C; Du Q; Li W; Deng R; Wang Q; Xu A; Shen J
    Mol Neurobiol; 2018 Dec; 55(12):9334-9348. PubMed ID: 29675572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
    Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
    Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease.
    Taravini IR; Larramendy C; Gomez G; Saborido MD; Spaans F; Fresno C; González GA; Fernández E; Murer MG; Gershanik OS
    Neuropharmacology; 2016 Feb; 101():576-89. PubMed ID: 25963416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
    Patricio F; Parra I; Martínez I; Pérez-Severiano F; Montes S; Aguilera J; Limón ID; Tizabi Y; Mendieta L
    Neurotox Res; 2019 Apr; 35(3):699-710. PubMed ID: 30607904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat.
    El Atifi-Borel M; Buggia-Prevot V; Platet N; Benabid AL; Berger F; Sgambato-Faure V
    Neurobiol Dis; 2009 May; 34(2):340-50. PubMed ID: 19233275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
    García J; Carlsson T; Döbrössy M; Nikkhah G; Winkler C
    Neurobiol Dis; 2011 Sep; 43(3):576-87. PubMed ID: 21600983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
    Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
    Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
    Berghauzen-Maciejewska K; Kuter K; Kolasiewicz W; Głowacka U; Dziubina A; Ossowska K; Wardas J
    Behav Brain Res; 2014 Sep; 271():343-53. PubMed ID: 24956561
    [TBL] [Abstract][Full Text] [Related]  

  • 54. L-DOPA treatment of parkinsonian rats changes the expression of Src, Lyn and PKC kinases.
    Napolitano M; Picconi B; Centonze D; Bernardi G; Calabresi P; Gulino A
    Neurosci Lett; 2006 May; 398(3):211-4. PubMed ID: 16529858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
    Ferrario JE; Rojas-Mayorquín AE; Saldaña-Ortega M; Salum C; Gomes MZ; Hunot S; Raisman-Vozari R
    J Neurochem; 2008 Oct; 107(2):443-52. PubMed ID: 18752647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The habenula couples the dopaminergic and the serotonergic systems: application to depression in Parkinson's disease.
    Sourani D; Eitan R; Gordon N; Goelman G
    Eur J Neurosci; 2012 Sep; 36(6):2822-9. PubMed ID: 22774942
    [TBL] [Abstract][Full Text] [Related]  

  • 60. L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease.
    Ghilardi MF; Feigin AS; Battaglia F; Silvestri G; Mattis P; Eidelberg D; Di Rocco A
    Parkinsonism Relat Disord; 2007 Apr; 13(3):146-51. PubMed ID: 17055764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.